In conclusion, CD19-ReTARGTPR effectively eliminates CD19-expressing cancer cells while avoiding several major limitations of CAR T cell and BiTE therapies, including excessive cytokine release, AICD, and escape due to diminished target antigen expression. The gene discussed is CD19; the disease is cancer.